Epiodyne
Douglas Crawford’s goal is to help entrepreneurial scientists create successful startups. To this end, Doug and his colleagues have systematically lowered the barriers between great ideas and successful companies. For instance, Doug created and manages MBC BioLabs. This state-of-the-art co-working laboratory program in San Francisco allows entrepreneurs to rapidly generate data without getting bogged down in facility management. Rather than spending months getting a facility up and running, MBC BioLabs startups can generate important data in their first week.
In the first 4 years, this program has helped launch 104 companies that have raised over 1.76B. This incubator program reflects Doug’s passion for startups and his eagerness to help entrepreneurs overcome challenges.
Doug is also the Managing Director of Mission Bay Capital and has overseen the investment in 45 companies, 9 of which have already enjoyed successful exits (Alector, Atreca, Calithera, Cell Design Labs, iPierian, Principia, Redwood Biosciences, True North, and Zephyrus). He is a board member of Avexegen, Epiodyne, Graphwear, Invenio, Magnamosis, Magnap, Mitokinin, SiteOne (observer), and Tangible Sciences.
Doug received his PhD in biochemistry from UCSF.
This person is not in any offices
Epiodyne
Epiodyne was founded to develop breakthrough small molecule medicines based upon novel insights into GPCR receptor pharmacology that were uncovered by leading researchers at UCSF, Stanford and Duke. They are using quantitative pharmacological and behavioral techniques to translate their insights into novel medicines for patients with opioid use disorder (OUD). They are backed by a syndicate of experienced biotech VCs and located in the Bay Area.